Drugs / 3'-aminomethyl-Nic r-EPA Conjugate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00598325 | Jan 2008 → Oct 2010 | — | Nabi Biopharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3'-aminomethyl-Nic r-EPA Conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00598325 ↗ |
| Known as | 3'AmNic-rEPA | “NicVAX, a nicotine vaccine (3'AmNic-rEPA), has been clinically evaluated” PMID 21270788 ↗ Jan 2011 |
| Modality | Vaccine | “NicVAX, a nicotine vaccine (3'AmNic-rEPA)” PMID 21270788 ↗ Jan 2011 |
| Route | Intramuscular | “1.0 ml injection IM given every 4 weeks” NCT00598325 ↗ |